Spruce Biosciences (NASDAQ:SPRB – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Risk and Volatility
Spruce Biosciences has a beta of 3.31, indicating that its stock price is 231% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Spruce Biosciences and Celularity, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spruce Biosciences | 1 | 1 | 10 | 0 | 2.75 |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Spruce Biosciences and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spruce Biosciences | N/A | -123.53% | -90.35% |
| Celularity | -345.45% | N/A | -77.94% |
Earnings & Valuation
This table compares Spruce Biosciences and Celularity”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spruce Biosciences | $4.91 million | 32.58 | -$38.97 million | ($39.78) | -1.40 |
| Celularity | $26.55 million | 1.57 | -$91.72 million | ($3.33) | -0.43 |
Spruce Biosciences has higher earnings, but lower revenue than Celularity. Spruce Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Summary
Spruce Biosciences beats Celularity on 8 of the 14 factors compared between the two stocks.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
